Please login to the form below

Not currently logged in
Email:
Password:

hepatitis B

This page shows the latest hepatitis B news and features for those working in and with pharma, biotech and healthcare.

Chinese biotechs aim PD-L1 antibody at hepatitis B

Chinese biotechs aim PD-L1 antibody at hepatitis B

and specifically hepatitis B. ... The deal stems from speculation that the immune-boosting activity of checkpoint inhibitors could have a role to play in infectious disease, and particularly chronic, hard-to-treat infections like hepatitis

Latest news

More from news
Approximately 7 fully matching, plus 77 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    hepatitis B virus (HBV). Strategic. collaboration ‐. development. $445m. Innate Pharma/. ... Manufacture and supply of CAR‐T cell therapy, Kymriah, for B‐cell acute lymphoblastic leukaemia.

  • No incentive for a cure No incentive for a cure

    Hepatitis C virus treatments like Maviret from AbbVie, which cures people with hard-to-treat genotype 3 after an 8. ... This is the route the NHS in the UK has taken with innovative hepatitis C treatments; it will only pay for the medication if a patient

  • Pharma deals in April 2015 Pharma deals in April 2015

    its SAR3419, an antibody-drug conjugate designed to treat diffuse large B-cell lymphoma (DLBCL) and other blood cancers. ... These are key markets for this product as more than 75% of all HCC cases occur in the APAC region, largely in association with

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Corporate acquisition. 545. Cytos Biotechnology/ OnCore. Access to virus like particle (VLP) platform for the treatment and prevention of hepatitis B with an option to other viral diseases.

  • Deal Watch table for September 2014 Deal Watch table for September 2014

    153. NeuroVive / OnCore. Licence and collaboration. NVP018 an oral sangamide-based 2nd generation cyclophilin inhibitor for hepatitis B.

More from intelligence
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics